Reason for request
Extension of indication
Clinical Benefit
Clinical Added Value
| no clinical added value |
EYLEA does not provide any improvement in actual benefit (level V, non-existent) compared with LUCENTIS for adults in the treatment of visual impairment due to macular oedema secondary to central retinal vein occlusion (CRVO). |
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
JWMZdeEaXenF5ZLD
